Corona Remedies Limited IPO: Issue Price, Listing Gain and Share Price Now
Corona Remedies Limited listed on 15-Dec-2025 at ₹1,437.2 against an issue price of ₹1,062 , a listing gain of +35.33%. It last traded at ₹2,164.5. This page is the record of that issue and what has happened to it since — reported figures only.
Corona Remedies Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹1,062 |
| Listing price (listing-day close) | ₹1,437.2 |
| Listing gain | +35.33% |
| Price now | ₹2,164.5 |
| Change from issue price | +103.81% |
| Change from listing-day close | +50.61% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Corona Remedies Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹1,062 |
| Issue size | ₹655.37 Cr |
| Offer for sale | ₹655.37 Cr |
| Issue opened | 08-Dec-2025 |
| Issue closed | 10-Dec-2025 |
| Listed on | 15-Dec-2025 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | JM Financial (left lead) |
How the Corona Remedies Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 293.80x |
| NII | 220.18x |
| Retail | 30.39x |
| Total | 144.54x |
Corona Remedies Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹13,231 Cr |
| Trailing P/E | 62.40x |
| Return on capital employed | 33.3% |
| Return on equity | 29.5% |
| 52-week high | ₹2,270 |
| 52-week low | ₹1,337 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Corona Remedies Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.